| Enochian BioSciences is a pre-clinical stage biotechnology company. Co.'s product candidates include: ENOB-HV-01 for autologous Human Immunodeficiency Virus (HIV) curative treatment; ENOB-HV-11 for preventive HIV vaccine; ENOB-HV-12 for therapeutic HIV vaccine; ENOB-HV-21 for HIV natural killer and gamma delta T-cell treatment or cure; ENOB-HV-31 for in vivo gene therapy; ENOB-HB-01 for hijacking Hepatitis B Virus polymerase; ENOB-CV-01 for coronavirus treatment; ENOB-CV-11 for coronavirus prophylaxis; ENOB-FL-01 for influenza treatment; ENOB-FL-11 for influenza prophylaxis; and ENOB-DC-11 for off the shelf dendritic cell vaccine for multiple solid tumors. We show 19 historical shares outstanding datapoints in our ENOB shares outstanding history coverage, used to compute ENOB market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ENOB market cap history over the course of time is important for investors
interested in comparing ENOB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ENOB versus a peer is one thing; comparing
ENOB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ENOB can fluctuate over the course of history.
With this page we aim to empower investors researching ENOB by allowing them to research the ENOB market cap history.